Health ❯ Healthcare ❯ Medical Research ❯ Oncology

Pancreatic Cancer

Tango Reports 92% Response Rate for Vopimetostat‑Daraxonrasib in Pancreatic Cancer

The company says the result supports moving the combination into a Phase 3 trial for first‑line MTAP‑deleted pancreatic cancer pending regulator discussions.

12 ARTICLES

3w ago

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

35 ARTICLES

4w ago

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

11 ARTICLES

last mo.

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

8 ARTICLES

2mo ago

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

3 ARTICLES

2mo ago

Experimental Pill Doubles Survival in Advanced Pancreatic Cancer Trial

7 ARTICLES

4mo ago

CNIO’s Triple-Drug Mouse Breakthrough on Pancreatic Cancer Moves Into a Cautious Preclinical Phase

16 ARTICLES

5mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

19 ARTICLES

5mo ago

Triple-Drug Strategy Wipes Out Pancreatic Tumors in Mice, Study Finds

3 ARTICLES

5mo ago

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models